Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-06

Clinical Trial Update: Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 [Phase 1]

View source ↗

Summary

Phase 1 study assessing how hepatic impairment affects the pharmacokinetics of PF-07321332 has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PF-07321332 (nirmatrelvir)

Snippet

Sponsor: Pfizer | Conditions: Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2023-09-06